The United States StuDy for EvalUating EndovasculaR TreAtments of Lesions in the Superficial Femoral Artery and Proximal Popliteal By usIng the Protege EverfLex NitInol STent SYstem II (DURABILITY II)

University of Wisconsin School of Medicine and Public Health, Madison, Wisc. Electronic address: .
Journal of vascular surgery: official publication, the Society for Vascular Surgery [and] International Society for Cardiovascular Surgery, North American Chapter (Impact Factor: 2.98). 05/2013; 58(1). DOI: 10.1016/j.jvs.2012.12.066
Source: PubMed

ABSTRACT OBJECTIVE: Angioplasty and stenting are options for revascularization of symptomatic femoral popliteal disease. Although angioplasty alone is effective in short lesions, longer lesions are often treated with stents. Multiple overlapping stents are expensive and may be associated with stent fracture. This trial evaluated the safety and efficacy of a single self-expanding stent up to 20 cm in length in patients with atherosclerotic disease of the superficial femoral artery (SFA) and proximal popliteal artery. METHODS: Patients with lesions >4 cm and <18 cm were enrolled in this nonrandomized, prospective, multicenter trial that evaluated the Protégé EverFlex Self-Expanding Peripheral Stent System (Covidien, Plymouth, Minn). The study's primary end points were the 30-day major adverse event rate and duplex ultrasound-assessed patency at 1 year. These were compared with published performance goals. A preplanned analysis was conducted for the primary effectiveness end points at 1 year. Follow-up, including history, ankle-brachial index, patient-reported outcomes, duplex ultrasound assessment, and radiographs, is planned through 3 years. There was core laboratory review of angiograms, ultrasound scans, and plain radiographs. A subgroup of patients was studied with graded treadmill testing. RESULTS: The study enrolled 287 patients (66% male; mean age, 68 years) with stenotic, restenotic, or occluded lesions of the SFA at 44 investigational sites in the United States and Europe. Systemic comorbidities included hypertension (88%), hyperlipidemia (86%), diabetes (43%), and prior SFA intervention (41%). The mean lesion length measured by the core laboratory was 89 mm. The mean normal-to-normal lesion length measured by sites was 110 mm. A total of 303 stents were implanted, and 95% of patients received a single stent. No major adverse events occurred at 30 days. At 1 year, primary outcome of duplex ultrasound stent patency was 67.7% in evaluable patients, and among 1-year secondary outcomes, the mean ankle-brachial index increased by 0.25. Walking Improvement Questionnaire scores improved in pain by 33.7, distance by 37.1, speed by 18.6, and stair climbing by 24.7. The Kaplan-Meier estimate of primary patency was 77.2%, primary assisted patency was 86.9%, and secondary patency was 87.3%. Rutherford clinical category improved in 83.5% of patients. Stent fracture rate was 0.4%. Matched absolute claudication distance was 412 feet greater and was not statistically different in this subgroup of 29 individuals. CONCLUSIONS: The results of DURABILITY II (StuDy for EvalUating EndovasculaR TreAtments of Lesions in the Superficial Femoral Artery and Proximal Popliteal By usIng the Protégé EverfLex NitInol Stent SYstem II) suggest that a new single stent strategy is safe and effective for the treatment of long lesions of the SFA and proximal popliteal arteries at 1 year.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Trotz initial guter Erfolge nach Angioplastie bei peripherer arterieller Verschlusskrankheit (pAVK) bilden Restenosen das Hauptproblem. Sie werden durch neointimale Hyperplasie verursacht und können mithilfe antiproliferativer Substanzen effektiv unterdrückt werden. Zur längerfristigen Hemmung werden medikamentenbeschichtete Ballonkatheter (,,drug-coated balloon“, DCB) und -“drug-coated stents“ (DCS) eingesetzt.Die vorliegende Arbeit gibt einen Überblick über die DCB-Entwicklung, die aktuell eingesetzten Systeme und die vorliegenden klinischen Studien. Die Evidenz in der Behandlung der femoropoplitealen Arterien wird diskutiert.Es wurde eine systematische elektronische Literaturrecherche in Datenbanken medizinischer Fachzeitschriften, international registrierter klinischer Studien und publizierter Kongressbeiträge zum DCB-Einsatz im infrainguinalen Bereich im Zeitraum 2008 bis Juli 2013 durchgeführt.Hauptvorteile der DCB sind, dass kein Metall im Gefäß zurückbleibt, die unmittelbare Freisetzung hoher Substanzkonzentrationen und ihre Einsetzbarkeit in Bereichen, in denen DCS bisher kontraindiziert sind. Die klinische Evidenz der ,,paclitaxel drug-coated balloon“ (PTX-DCB) der 1. Generation wurde in verschiedenen kontrollierten randomisierten Studien aufgezeigt.In Abhängigkeit von der Läsionsart und dem Läsionsort sind DCB geeignet bei In-Stent-Restenosen, Restenosen oder in Bereichen der A. poplitea oder bei Seitenästen der A. profunda, in denen eine Stent-Applikation kontraindiziert ist.
    Gefässchirurgie 01/2013; 18(6). DOI:10.1007/s00772-013-1226-5 · 0.24 Impact Factor
  • Journal of Endovascular Therapy 12/2013; 20(6):767-9. DOI:10.1583/13-4430C.1 · 3.59 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Widespread use of self-expanding nitinol stent-based endovascular treatment (EVT) for femoropopliteal (FP) lesions has been fueled by its less-invasive nature and modest durability; however, prevalence, predictors and prognosis of in-stent occlusion are undefined and were investigated here. This study entailed a multicenter, retrospective analysis of a prospectively maintained database. Between January 2004 and December 2011, 2447 de novo FP lesions (mean length, 143 ± 87 mm; 52% chronic total occlusions) from 2008 patients (mean age, 73.0 ± 9.2 years; 71% male; 61% diabetics; 32% critical limb ischemia; and 24% on hemodialysis) were treated with nitinol stent-based EVT. Study outcome was in-stent occlusion: rates (1, 3, and 5 years), predictors and association with limb prognosis. In-stent occlusion rate was 5.2%, 11.2%, and 16.4% at 1, 3, and 5 years, respectively (mean follow-up, 2.3 ± 1.7 years). Female sex, critical limb ischemia, and Transatlantic Inter-Society Consensus II class C/D (multivariate Cox proportional hazard ratio [HR], 1.75, 1.49, and 3.34, respectively) were independent predictors of in-stent occlusion after FP stenting, which was associated with poor limb prognosis (major amputation, HR 6.35; major adverse limb event, major adverse limb event, HR, 21.1). Moderate in-stent occlusion rates were observed after nitinol stent-based EVT. Closer attention is warranted with high-risk cases because of poorer limb prognosis.
    Journal of vascular surgery: official publication, the Society for Vascular Surgery [and] International Society for Cardiovascular Surgery, North American Chapter 12/2013; DOI:10.1016/j.jvs.2013.10.050 · 2.98 Impact Factor
Show more


Available from